When anticancer antibodies target cancer cells by binding to a cancer antigen, the Fc region of the antibodies may recruit NK cells by binding to CD16 (FcγRIII) on NK cells, triggering Antibody-Dependent Cellular Cytotoxicity (ADCC), by which tumor-targeting antibody drugs exert their antitumor effects (Pereira et al., 2018). This evidence concerns the gene FCGR3A and cancer.